Medical Oncology Prof. Dr. Özkan Kanat
✓ Medically verified profileProf. Dr. Özkan Kanat
✓ Medically verified profile
About Prof. Dr. Özkan Kanat
Quick answer
Prof. Dr. Özkan Kanat is a Medical Oncology specialist at Acibadem Bursa Hospital in Bursa with 31+ years of experience.
He treats metastatic and treatment-refractory metastatic colorectal cancer, colorectal liver metastases, pancreatic cancer, advanced gastric cancer, periampullary adenocarcinoma, metastatic and triple-negative breast cancer, and colon cancer, and handles HER2-targeted therapy, targeted therapy for advanced gastric cancer, anti-stromal therapy for pancreatic cancer, and platinum-induced neurotoxicity. He offers consultations in Turkish and English, including…
Prof. Özkan Kanat is a physician and pharmacologist with a PhD in Pharmacology from Uludağ University (2013). He combines clinical expertise and research experience to improve patient care and therapeutic outcomes. Since 2019 he has been affiliated with Acıbadem Health Group, where he applies his knowledge in pharmacology to clinical practice, treatment planning, and interdisciplinary collaboration. He is committed to evidence-based medicine, ongoing professional development, and translating research findings into practical solutions for patients and healthcare teams.
Areas of Expertise
Conditions treated and procedures performed by this specialist.
Education
- 2013Uludag University / Pharmacology / PhD
- 2001Uludag University Faculty of Medicine Medical Oncology
- 2000Uludag University Faculty of Medicine Internal Medicine
- 1995Ondokuzmayıs University Faculty of Medicine
Professional Experience
- 2019Acibadem Health Group
- 2012Vall d”Hebron Institute of Oncology Gastrointestinal and Phase I units / Barcelona (with Prof. Joseph Tabernero)
- 2011Fox Chase Cancer Center Philadelphia Externship Organization
- 2011The University of North Carolina at Chapel Hill Cancer Hospital / Gastrointestinal Cancer Unit (with Prof. Bert O?Neil and Prof. Richard Goldberg)
- 2011Memorial Sloan Kettering Cancer Center / Gastrointestinal Cancer Unit (with Prof. Nancy Kemeny) / New York, United States of America
- 1995–2019Uludag University Faculty of Medicine Department of Internal Medicine / Division of Medical Oncology
Selected Publications
- Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status World J Clin Cases. 2018 Oct 6;6(11):418-425. doi: 10.12998/wjcc.v6.i11.418. Review. Kanat O, Ertas H, Caner B.
- Shattering the castle walls: Anti-stromal therapy for pancreatic cancer World J Gastrointest Oncol. 2018 Aug 15;10(8):202-210. doi: 10.4251/wjgo.v10.i8.202. Review. Kanat O, Ertas H.
- Platinum-induced neurotoxicity: A review of possible mechanisms World J Clin Oncol. 2017 Aug 10;8(4):329-335. doi: 10.5306/wjco.v8.i4.329. Review. Kanat O, Ertas H, Caner B.
- Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes Acta Gastroenterol Belg. 2017 Jan-Mar;80(1):31-37. Uğraş N, Yerci Ö, Özgün G, Deligönül A, Dündar HZ, Sarkut P, Kanat Ö.
- Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer J BUON. 2016 May-Jun;21(3):564-9 Deligonul A, Evrensel T, Avci N, Ugras N, Ture M, Cubukcu E, Hartavi M, Fatih Olmez O, Kurt E, Tolunay S, Kanat O, Manavoglu O.
- Current treatment options for patients with initially unresectable isolated colorectal liver metastases World J Clin Oncol. 2016 Feb 10;7(1):9-14. doi: 10.5306/wjco.v7.i1.9. Kanat O.
- Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients Asian Pac J Cancer Prev. 2016;17(3):1175-9. Gorukmez O, Yakut T, Gorukmez O, Sag SO, Karkucak M, Kanat O.
- Targeted therapy for advanced gastric cancer: A review of current status and future prospects World J Gastrointest Oncol. 2015 Dec 15;7(12):401-10. doi: 10.4251/wjgo.v7.i12.401. Review. Kanat O, O”Neil B, Shahda S.
- linical significance of adiponectin expression in colon cancer patients J Cancer Res Ther. 2014 Apr-Jun;10(2):347-53. doi: 10.4103/0973-1482.136634. Canhoroz M, Kanat O, Saraydaroglu O, Buluc E, Avci N, Cubukcu E, Olmez OF, Manavoglu O.
- Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer Contemp Oncol (Pozn). 2014;18(1):34-8. doi: 10.5114/wo.2014.40454. Epub 2014 Feb 28. Cubukcu E, Olmez OF, Kanat O, Kabul S, Canhoroz M, Avci N, Hartavi M, Deligonul A, Cubukçu S, Manavoglu O.
Frequently Asked Questions
What is Dr. Özkan Kanat's specialty?
Which hospital does Dr. Özkan Kanat practise at?
What languages can I use when consulting Dr. Özkan Kanat?
How can I book an appointment with Dr. Özkan Kanat?
Is an online video consultation available with Dr. Özkan Kanat?
How many years of experience does Dr. Özkan Kanat have?
Can international patients arrange treatment with Dr. Özkan Kanat?
How do I get a second opinion involving Dr. Özkan Kanat?
A dedicated team, from first message to follow-up
Our international patient office coordinates your appointment, travel and treatment at JCI-accredited Acıbadem hospitals — and stays with you in your own language, every step of the way.
Schedule your appointment with Prof. Dr. Özkan Kanat
Choose a date and time that suits you. Our international patient team will check availability and confirm your appointment — usually within 24 hours.
- 1Choose your date & timePick a preferred day and time slot for your visit.
- 2Share your detailsTell us how to reach you and anything we should know.
- 3We confirm with youOur team confirms the appointment by phone or email.
Request your appointment
This request goes directly to this doctor’s schedule.
Your information stays strictly confidential and is used only to arrange your care.
